register

News & Trends - MedTech & Diagnostics

Zimmer Biomet and Device Technologies announce partnership in orthopaedics

Health Industry Hub | April 12, 2021 |

MedTech News: Zimmer Biomet and Device Technologies, both major powerhouses in musculoskeletal healthcare, today announced a partnership to improve orthopaedic patient outcomes across Australia and New Zealand.

Zimmer Biomet has appointed Device Technologies as an exclusive distributor in Australia and New Zealand for its Sports Medicine and Surgical product portfolios from 12 April 2021, with Foot & Ankle and Trauma product portfolios to follow on 31 May 2021.

“The partnership with Device Technologies underscores a new business model that focuses on Zimmer Biomet’s core strengths while leveraging Device Technologies’ distribution and support network for greater growth in the target product portfolios in Australia and New Zealand,” said Warren Ballinger, Zimmer Biomet’s ANZ President. “The Device Technologies network will provide Zimmer Biomet with greater market penetration across Sports Medicine, Surgical, Foot & Ankle and Trauma. It will allow us to focus more on our hip, knee, shoulder, elbow, CMFT, Spine and Early Intervention product ranges as well as our suite of technology-based solutions,” he added.

“Partnering with Zimmer Biomet is an exciting step forward for Device Technologies. We are confident in the shared values between the two companies and that Zimmer Biomet’s product offering will complement our orthopaedic product portfolio and service Device Technologies customers well,” said Mick Trevaskis, Device Technologies CEO. “It’s a partnership that will see both companies proceed well together into the future.”

With over 90 years in the industry, Zimmer Biomet continues to be a driving force in musculoskeletal healthcare. Its unwavering focus on the needs of patients and surgeons drives the innovative and technologically advanced product solutions they offer. By combining with the extensive orthopaedic partnership network and loyal customer base of Device Technologies, Zimmer Biomet intends to further consolidate and strengthen its presence and reputation in Australia and New Zealand.

With 28 years’ experience in the orthopaedic market in Australia and New Zealand, Device Technologies boasts a history of consistent sales success; in 2019 the Device Technologies orthopaedic business had over 55% market share in Sports Medicine in Australia.

Zimmer Biomet’s product offerings will complement Device Technologies’ holistic portfolio, encompassing advanced orthopaedic products and technologies, product education, dedicated technical service and thorough clinical support. At present, 85% of orthopaedic surgeons in Australia and New Zealand are Device Technologies customers and 80% of current orthopaedic registrars across the two countries have participated in educational courses through Device Technologies.


ESG

Surgeons lead push for $1.5 million hospital sustainability project

Surgeons lead push for $1.5 million hospital sustainability project

Health Industry Hub | October 23, 2024 |

ESG: Australia’s healthcare sector contributes 7% of the country’s total emissions. The Royal Australasian College of Surgeons (RACS) has joined […]

More


News & Trends - MedTech & Diagnostics

AI-assisted colonoscopy boosts polyp and adenoma detection

AI-assisted colonoscopy boosts polyp and adenoma detection

Health Industry Hub | October 23, 2024 |

MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]

More


News & Trends - Pharmaceuticals

'Every day of delay is costing Australian lives', says Rare Cancers Australia CEO

‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO

Health Industry Hub | October 23, 2024 |

Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]

More


News & Trends - Pharmaceuticals

Government's silence on Senate report leaves cancer patients in limbo

Government’s silence on Senate report leaves cancer patients in limbo

Health Industry Hub | October 23, 2024 |

Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]

More


This content is copyright protected. Please subscribe to gain access.